Oral hypoglycemic agents

 

 Launch of ‘Dimit XR Extended Release Tablet’

 

 


 

KyungDong Pharm Co., Ltd. launched the oral hypoglycemic agent ‘Dimit XR extended-release tablet (metformin hydrochloride 500mg)’ on April 15th.
Dymit XR extended-release tablet is a product with the same ingredient content as the existing Dymit tablet (metformin hydrochloride 500 mg). It is an oral hypoglycemic agent that reduces gastrointestinal side effects by controlling the release rate of the drug and improves patient compliance with medication by taking it once a day.
Metformin has recently been selected as a first-line drug in the diabetes treatment guidelines (American Diabetes Association, ADA), and its prescriptions are increasing worldwide. In some studies, it has been recognized as the only oral hypoglycemic agent that extends the lifespan of patients.
With the launch of Dymit XR extended-release tablets, KyungDong Pharm Co., Ltd. has further improved the completeness of its oral hypoglycemic agent product line, including Pictos tablets (pioglitazone 15 mg), which were launched in August of last year, and the existing products Glymine tablets (glimepiride 2 mg), Dymit tablets, and Dymit tablets 250 mg, thereby strengthening its image as a company specializing in circulatory disease treatments.


《Product Information》

▷ Ingredient content: Metformin HCl 500mg
▷ Efficacy: Treatment of type 2 diabetes in adults
▷ Dosage: The general initial dose is 1 tablet once a day with dinner.
When increasing the dose, it must be increased by 500 mg per week, and the maximum dose is 2,000 mg.
If blood sugar control is not achieved even after administering up to 2,000 mg per day, take 1,000 mg per day.
Two-dose administration is also considered.
▷ Appearance: White or light yellow, oblong tablet with convex sides
▷ Insurance price: 106 won/tablet
▷ Packaging unit: 90 tablets (PTP)
▷ Insurance code: A17604091

* For further details, please refer to the product manual.